| 496.13 0.37 (0.07%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 583.06 |
1-year : | 681.02 |
| Resists | First : | 499.2 |
Second : | 583.06 |
| Pivot price | 476.83 |
|||
| Supports | First : | 450.38 |
Second : | 420.2 |
| MAs | MA(5) : | 492.11 |
MA(20) : | 471 |
| MA(100) : | 506.7  |
MA(250) : | 532.68 |
|
| MACD | MACD : | 7.3 |
Signal : | 3 |
| %K %D | K(14,3) : | 95.5 |
D(3) : | 93.4 |
| RSI | RSI(14): 64.7 |
|||
| 52-week | High : | 609.84 | Low : | 415.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TMO ] has closed below upper band by 20.7%. Bollinger Bands are 36% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 499.95 - 501.96 | 501.96 - 504.04 |
| Low: | 484.67 - 486.77 | 486.77 - 488.92 |
| Close: | 492.38 - 496.02 | 496.02 - 499.77 |
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Sun, 03 Dec 2023
Guru Fundamental Report for TMO - Peter Lynch - Nasdaq
Fri, 01 Dec 2023
Thermo Fisher Scientific Extends the Expiration of Tender Offer for ... - Investors
Fri, 01 Dec 2023
We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of ... - Yahoo Finance
Thu, 30 Nov 2023
Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering - Nasdaq
Wed, 29 Nov 2023
Thermo Fisher Scientific Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Wed, 22 Nov 2023
Is Thermo Fisher Scientific Inc (TMO) Stock a Attractive Value? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 386 (M) |
| Shares Float | 386 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 91.8 (%) |
| Shares Short | 2,750 (K) |
| Shares Short P.Month | 2,410 (K) |
| EPS | 15.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 117.31 |
| Profit Margin | 13.6 % |
| Operating Margin | 18.4 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 13.2 % |
| Qtrly Rev. Growth | -1 % |
| Gross Profit (p.s.) | 49.17 |
| Sales Per Share | 112.37 |
| EBITDA (p.s.) | 28.05 |
| Qtrly Earnings Growth | 16.6 % |
| Operating Cash Flow | 8,170 (M) |
| Levered Free Cash Flow | 4,630 (M) |
| PE Ratio | 32.49 |
| PEG Ratio | 10.7 |
| Price to Book value | 4.22 |
| Price to Sales | 4.41 |
| Price to Cash Flow | 23.44 |
| Dividend | 0.34 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|